{"id":"docetaxel-lh-rh-analogues","safety":{"commonSideEffects":[{"rate":"75-90","effect":"Neutropenia"},{"rate":"50-70","effect":"Anemia"},{"rate":"25-40","effect":"Thrombocytopenia"},{"rate":"20-35","effect":"Neuropathy (peripheral)"},{"rate":"40-60","effect":"Fatigue"},{"rate":"30-50","effect":"Nausea/vomiting"},{"rate":"50-80","effect":"Hot flashes (from LH-RH)"},{"rate":"20-30","effect":"Fluid retention"},{"rate":"5-10","effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL412716","moleculeType":"Protein","molecularWeight":"1330.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel is a taxane chemotherapy agent that stabilizes microtubules and prevents their disassembly, leading to mitotic arrest and apoptosis in rapidly dividing cells. LH-RH (luteinizing hormone-releasing hormone) analogues suppress the hypothalamic-pituitary-gonadal axis, reducing circulating testosterone levels. This combination targets both the proliferative capacity of cancer cells and their hormonal dependence, particularly effective in hormone-sensitive malignancies.","oneSentence":"Docetaxel inhibits microtubule depolymerization to arrest cancer cell division, while LH-RH analogues suppress testosterone production to reduce androgen-dependent tumor growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:44:21.630Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-sensitive prostate cancer"},{"name":"Hormone-sensitive prostate cancer"}]},"trialDetails":[{"nctId":"NCT01224405","phase":"PHASE3","title":"Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent Chemotherapy","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2010-04","conditions":"Advanced Prostate Cancer","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Docetaxel + LH-RH analogues","genericName":"Docetaxel + LH-RH analogues","companyName":"University of Turin, Italy","companyId":"university-of-turin-italy","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel inhibits microtubule depolymerization to arrest cancer cell division, while LH-RH analogues suppress testosterone production to reduce androgen-dependent tumor growth. Used for Metastatic castration-sensitive prostate cancer, Hormone-sensitive prostate cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}